Etravirine Tablet
Brand names: Etravirine, Intelence
Category: Antiviral
FDA status: To Be Discontinued · Last FDA update: Apr 28, 2026 · First posted: Apr 28, 2026 · 1 manufacturers, 2 listed presentations
As of Apr 28, 2026, the FDA lists Etravirine Tablet as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Etravirine, Tablet, 100 mg (NDC 10147-0570-1) NDC 10147-0570-1 |
Janssen Research and Development | Not specified | Discontinuation of the manufacture of the drug |
| Intelence, Tablet, 100 mg (NDC 59676-570-01) NDC 59676-570-01 |
Janssen Research and Development | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Antiviral medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Etravirine Tablet (FDA data as of Apr 28, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Etravirine Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/etravirine-tablet.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).